Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.96 Insider Own12.45% Shs Outstand83.44M Perf Week-3.32%
Market Cap293.93M Forward P/E- EPS next Y-2.45 Insider Trans-1.37% Shs Float73.74M Perf Month-8.64%
Income-163.66M PEG- EPS next Q-0.66 Inst Own61.76% Short Float2.95% Perf Quarter-14.04%
Sales0.00M P/S- EPS this Y-63.13% Inst Trans-0.16% Short Ratio8.27 Perf Half Y15.56%
Book/sh5.99 P/B0.58 EPS next Y7.87% ROA-27.48% Short Interest2.18M Perf Year-10.74%
Cash/sh6.43 P/C0.54 EPS next 5Y- ROE-29.16% 52W Range2.77 - 4.60 Perf YTD14.43%
Dividend Est.- P/FCF- EPS past 5Y-71.56% ROI-32.36% 52W High-24.13% Beta0.18
Dividend TTM- Quick Ratio13.28 Sales past 5Y104.50% Gross Margin- 52W Low26.22% ATR (14)0.17
Dividend Ex-Date- Current Ratio13.28 EPS Y/Y TTM-49.18% Oper. Margin0.00% RSI (14)41.76 Volatility5.08% 4.63%
Employees75 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom3.50 Target Price3.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-76.88% Payout- Rel Volume0.76 Prev Close3.44
Sales Surprise- EPS Surprise-43.93% Sales Q/Q- EarningsMay 14 AMC Avg Volume263.47K Price3.49
SMA20-5.12% SMA50-6.75% SMA200-0.99% Trades Volume200,414 Change1.45%
Date Action Analyst Rating Change Price Target Change
Aug-10-23Downgrade JP Morgan Neutral → Underweight
Jan-06-22Downgrade Morgan Stanley Equal-Weight → Underweight $14 → $7
Nov-18-21Downgrade SVB Leerink Outperform → Mkt Perform
Oct-20-21Downgrade JP Morgan Overweight → Neutral $61 → $16
Oct-05-21Downgrade Morgan Stanley Overweight → Equal-Weight $55
Nov-25-20Initiated Evercore ISI Outperform
Nov-24-20Initiated William Blair Outperform $60
Nov-24-20Initiated Morgan Stanley Overweight $49
Nov-24-20Initiated JP Morgan Overweight $45
Jun-05-24 07:00AM
May-29-24 07:00AM
May-22-24 07:00AM
May-15-24 09:01AM
May-14-24 04:05PM
07:00AM Loading…
May-07-24 07:00AM
Apr-29-24 07:00AM
Mar-27-24 07:00AM
Feb-29-24 10:03AM
Feb-28-24 04:58PM
Feb-21-24 07:00AM
Jan-10-24 09:30AM
Jan-08-24 04:05PM
Jan-03-24 07:00AM
07:00AM Loading…
Nov-13-23 07:00AM
Nov-09-23 03:57PM
Nov-08-23 04:05PM
Nov-02-23 07:00AM
Nov-01-23 07:00AM
Oct-24-23 12:30PM
Sep-06-23 07:00AM
Aug-09-23 06:58AM
Aug-08-23 04:05PM
Aug-01-23 07:00AM
Jun-15-23 07:00AM
Jun-05-23 04:20PM
May-30-23 07:00AM
07:02PM Loading…
May-26-23 07:02PM
May-23-23 04:05PM
May-10-23 11:53AM
May-09-23 10:09AM
May-08-23 04:05PM
May-01-23 04:05PM
Apr-25-23 07:00AM
Apr-12-23 07:00AM
Mar-14-23 07:00AM
Mar-08-23 07:00AM
Mar-02-23 09:20PM
Feb-28-23 04:05PM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Feb-15-23 04:05PM
Feb-13-23 08:22AM
Feb-07-23 07:00AM
Jan-09-23 07:00AM
Jan-04-23 07:00AM
Dec-16-22 11:10AM
Nov-29-22 07:00AM
Nov-22-22 07:00AM
Nov-19-22 09:46AM
Nov-10-22 12:00PM
Nov-08-22 04:05PM
Nov-07-22 04:05PM
Nov-04-22 08:36AM
Nov-03-22 07:00AM
Nov-02-22 11:14AM
Oct-31-22 07:00AM
Oct-18-22 10:58AM
Sep-27-22 09:53AM
Sep-26-22 09:33AM
Sep-13-22 09:56AM
Sep-07-22 07:00AM
Sep-06-22 08:18AM
Aug-09-22 06:00AM
Aug-08-22 04:30PM
Aug-01-22 07:00AM
Jul-13-22 12:00PM
Jul-11-22 07:00AM
Jul-07-22 08:45AM
Jul-02-22 10:23AM
Jun-12-22 09:37AM
Jun-01-22 07:00AM
May-25-22 06:20AM
May-11-22 10:28AM
May-10-22 07:00PM
May-03-22 04:05PM
Apr-01-22 05:13AM
Mar-30-22 12:48PM
Mar-28-22 07:00AM
Mar-21-22 10:04AM
Feb-28-22 10:00PM
Feb-22-22 07:00AM
Feb-16-22 02:19PM
Feb-14-22 09:31AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Feb-09-22 07:00AM
Feb-02-22 05:38PM
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Polsky BruceDirectorJun 20 '24Sale3.4917,54461,14465,606Jun 21 05:59 PM
Adams Jerome M.DirectorJun 16 '24Option Exercise0.0033,150033,150Jun 18 05:00 PM
Duncan Barbara GayleDirectorJun 16 '24Option Exercise0.0033,150033,150Jun 18 05:00 PM
Polsky BruceDirectorJun 16 '24Option Exercise0.0033,150083,150Jun 18 05:00 PM
BERGER FRANKLIN MDirectorJun 16 '24Option Exercise0.0033,1500811,503Jun 18 05:00 PM
Lucidi BrunoDirectorJun 16 '24Option Exercise0.0033,150083,150Jun 18 05:00 PM
Murphy Polly A.DirectorJun 16 '24Option Exercise0.0033,150056,445Jun 18 05:00 PM
Sommadossi Jean-PierrePresident, CEO, and ChairmanJun 05 '24Sale4.001,0064,0245,923,994Jun 07 06:34 PM
Sommadossi Jean-PierrePresident, CEO, and ChairmanFeb 01 '24Sale3.8556,910218,819116,557Feb 02 09:30 PM
Horga Maria ArantxaChief Medical OfficerFeb 01 '24Sale3.8415,87060,96325,664Feb 02 09:29 PM
Corcoran AndreaSee RemarksFeb 01 '24Sale3.8415,84360,915670,208Feb 02 09:31 PM
Hammond Janet MJChief Development OfficerFeb 01 '24Sale3.8414,02953,91335,362Feb 02 09:24 PM
Foster WayneEVP, Chief Accounting OfficerFeb 01 '24Sale3.8412,47747,90420,857Feb 02 09:26 PM
Vavricka JohnChief Commercial OfficerFeb 01 '24Sale3.8411,81945,42021,515Feb 02 09:25 PM